Tumor necrosis factor-α and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin a

Journal of Investigative Dermatology

Volumn 134, Issue 5, 2014, Pages 1470-1473

  Tanaka, Ryo ^a   Donovan, Nicholas C ^a   Yu, Qiang ^b   Irie, Reiko F ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; TUMOR NECROSIS FACTOR ALPHA; TRANSCRIPTION FACTOR EZH2; TRICHOSTATIN A;

APOPTOSIS; CELL DEATH; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE REPRESSION; HETEROCHROMATIN; HISTONE MODIFICATION; HUMAN; LETTER; MELANOMA CELL; PHENOTYPE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BREAST CANCER CELL LINE; CELL SURVIVAL; EPIGENETICS; HISTONE METHYLATION; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSYLHOMOCYSTEINASE; APOPTOSIS; CELL LINE, TUMOR; HISTONES; HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900853369     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.489     Document Type: Letter

References (15)

1. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361-71
2. Chang CJ, Hung MC (2011) The role of EZH2 in tumour progression. Br J Cancer 106:243-7
3. Greenberg ES, Chong KK, Huynh KT et al. (2012) Epigenetic biomarkers in skin cancer. Cancer Lett 12:371-82
4. Hoshimoto S, Kuo CT, Chong KK et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
5. Kondo Y, Shen L, Cheng AS et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741-50
6. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705
7. Landsberg J, Kohlmeyer J, Renn M et al. (2012) Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-6
8. McHugh JB, Fullen DR, Ma L et al. (2007) Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 34:597-600
9. Miranda TB, Cortez CC, Yoo CB et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8:1579-88
10. Ohm JE, McGarvey KM, Yu X et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237-42
11. Schlesinger Y, Straussman R, Keshet I et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-6
12. Shinojima T, Yu Q, Huang SK et al. (2012) Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 7:1279-89
13. Sullivan KE, Reddy AB, Dietzmann K et al. (2007) Epigenetic regulation of tumor necrosis factor alpha. Mol Cell Biol 27:5147-60
14. Tan J, Yang X, Zhuang L et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050-63
15. Tanemura A, Terando AM, Sim MS et al. (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801-7